C4 Therapeutics is advancing its lead myeloma degrader, cemsidomide, toward an accelerated‑approval pathway: the MOMENTUM Phase II single‑arm study (~100 patients) has started with management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results